Orexin Receptors (Hypocretin Receptor) Antagonist Market - Size, Share, and Analysis, 2018-2026

Orexin (hypocretin) is a neuropeptide produced by the lateral hypothalamus which regulates the wakefulness, appetite, arousal and other habits. Orexin receptor antagonist is the new class of drugs are used in the treatment of insomnia.

Suvorexant, is a dual orexin receptor antagonist drug that blocks both pathways of OX1R and OX2R. It develops sleep by the binding inhibition of orexin A and B, neuropeptides that promote wakefulness. Approximately 70,000 orexin neurons are present in the human brain, located in the perifornical lateral hypothalamus, which send signals throughout the brain and spinal cord.

Get PDF Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2522

The main growth driver for the Orexin receptors antagonist market is the rising cases of insomnia. Insomnia is caused by plenty of reasons such as anxiety, stress and depression. Lifestyle problems can trigger insomnia like irregular sleeping patters, drinking alcohol and smoking tobacco products before going to bed. Rising geriatric population, increased stress levels in urban population also results into insomnia. According to American Academy of Sleep Medicine AASM) as reported in 2014 insomnia affects 30% of adults, 15-20% have short term insomnia and 10% of adults have chronic insomnia worldwide.

Growing awareness about insomnia and penetration of Belsomra into the market is expected to create more demand in ORA market. Moreover, studies are being conducted whether suvorexant can be used to treat depression and anxiety so that the ORA market can witness further growth.

Though suvorexant (Orexin Receptors Antagonist) is the best drug available against insomnia, other classes of drugs such as Benzodiazepines, Non-benzodiazepines, Antidepressants, Melatonin Antagonist and medical devices like 2Breathe Sleep Inducer, Sleep Shepherd Blue, Dreem Headband, Fisher Wallace Stimulator, SR1 Delta Sleeper can also be used to treat insomnia which can negatively impede the market growth. Moreover, in National Sleep Foundation (NSF) stated that in the year 2010 only 15% of people were diagnosed with insomnia and only 6% receive the treatment for the same. General negligence among the people about insomnia and the side effects of drugs such as headache, sleepiness, next day drowsiness, weight loss restricts the patients from using this medication.

Furthermore, clinical studies by NCBI in 2015 showed the placebo treatment for insomnia is also effective for the patients which hampers the growth of ORA market.

Report with Discount Available @ https://www.coherentmarketinsights.com/insight/request-discount/2522

North America is leading the Orexin receptors antagonist market. Rising demand for insomnia treatment in the U.S. and Canada coupled with increase in awareness, and high healthcare spending are anticipated to drive the market. Moreover, high prevalence of insomnia among geriatric population in the U.S. are expected to increase the demand. According to AASM in 2017 30-50% population of U.S. over the age of 60 has developed insomnia.

In Asia Pacific, China is expected to show lucrative growth in the market owing to high prevalence of insomnia. According to China National Knowledge Interne (CNKI) in 2017 15% of China’s population is suffering from insomnia aging 43 and above From the Journal of Community Medicine & Health Education as reported in 2017 in India 72% of population above the age of 60 has insomnia. Asia Pacific is anticipated to witness significant growth in near future because of shift-work disorder and increasing stress level is expected to increase the number of paitents in Asia Pacific. In addition, favorable reimbursement policies for therapeutic products, strong product pipeline, and rising stress level are other reasons contributing to the growth.

Click To Continue Reading On Orexin Receptors (Hypocretin Receptor) Antagonist Market

Key competitors in the global Orexin receptors antagonist market include Merck & Co. Inc., Sanofi, Pfizer, Inc., Takeda Pharmaceutical Company Ltd., Purdue Pharmaceuticals L.P., Eisai, Co. Ltd., Meda Consumer Healthcare Inc., Pernix Therapeutics, Vanda Pharmaceuticals, and ECR Pharmaceuticals.

About Coherent Market Insights:

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link :https://www.coherentmarketinsights.com/phase-xs,

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Contact US: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel : +1-206-701-6702 Email: sales@coherentmarketinsights.com Website: https://www.coherentmarketinsights.com